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Background: The aim of the present study was to determine the effect of calcium phosphate and/or vitamin D3
on bone and mineral metabolism.
Methods: Sixty omnivorous healthy subjects participated in the double-blind, placebo-controlled parallel designed
study. Supplements were tricalcium phosphate (CaP) and cholecalciferol (vitamin D3). At the beginning of the study
(baseline), all subjects documented their normal nutritional habits in a dietary record for three successive days. After
baseline, subjects were allocated to three intervention groups: CaP (additional 1 g calcium/d), vitamin D3 (additional
10 μg/d) and CaP + vitamin D3. In the first two weeks, all groups consumed placebo bread, and afterwards, for eight
weeks, the test bread according to the intervention group. In the last week of each study period (baseline, placebo,
after four and eight weeks of intervention), a faecal (three days) and a urine (24 h) collection and a fasting blood
sampling took place. Calcium, phosphorus, magnesium and iron were determined in faeces, urine and blood. Bone
formation and resorption markers were analysed in blood and urine.
Results: After four and eight weeks, CaP and CaP + vitamin D3 supplementations increased faecal excretion of
calcium and phosphorus significantly compared to placebo. Due to the vitamin D3 supplementations (vitamin D3,
CaP + vitamin D3), the plasma 25-(OH)D concentration significantly increased after eight weeks compared to
placebo. The additional application of CaP led to a significant increase of the 25-(OH)D concentration already after
four weeks. Bone resorption and bone formation markers were not influenced by any intervention.
Conclusions: Supplementation with daily 10 μg vitamin D3 significantly increases plasma 25-(OH)D concentration.
The combination with daily 1 g calcium (as CaP) has a further increasing effect on the 25-(OH)D concentration. Both
CaP alone and in combination with vitamin D3 have no beneficial effect on bone remodelling markers and on the
metabolism of calcium, phosphorus, magnesium and iron.
Trial registration: NCT01297023
Keywords: Vitamin D, Calcium, Phosphorus, Magnesium, Iron, Human study, Bone remodelling* Correspondence: b6jage@uni-jena.de
1Department of Nutritional Physiology, Institute of Nutrition, Friedrich Schiller
University of Jena, Dornburger Str, 24, D-07743, Jena, Germany
Full list of author information is available at the end of the article
© 2014 Trautvetter et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Trautvetter et al. Nutrition Journal 2014, 13:6 Page 2 of 9
http://www.nutritionj.com/content/13/1/6Background
Vitamin D is of large importance for homeostasis of
calcium and bone metabolism. For humans, there are two
ways for an adequate supply with vitamin D: Firstly, via
cutaneous synthesis under UVB exposure, and secondly,
via intake with the diet [1]. International scientific literature
indicated a worldwide problem of vitamin D deficiency [2].
According to Hintzpeter et al., 57% of men and 58% of
women in Germany had 25-hydroxyvitamin D (25-(OH)D)
concentrations below the recommended concentration of
50 nmol/l [3]. Furthermore, the optimal concentration is
defined as a 25-(OH)D > 75 nmol/l [4]. In the first place,
vitamin D is responsible for maintaining the extracellular
calcium concentrations by controlling absorption of cal-
cium and by direct effects on bone and on parathormone
(PTH) secretion [2]. In recent years, vitamin D gained
increasing attention because of its association with the
risk of overall mortality, diabetes, cancer, musculoskeletal
disorders, mental and physical performance, hypertension
and cardiovascular diseases [5,6].
The beneficial effects of calcium phosphate mainly focus
on the intestinal metabolism, e.g., bile acid metabolism,
fatty acid excretion, and modulation of the gut microbiota
[7-10]. Calcium from tricalcium phosphate (CaP, a water-
insoluble compound at neutral pH value), is partly absorbed
in the human gut; but the main part of the calcium and
phosphorus is precipitated to amorphous calcium phos-
phate in the gut, and thus, not absorbed [11]. Nevertheless,
CaP showed in combination with vitamin D3 beneficial
modulation on bone metabolism in elderly women [12].
The aim of the present study was to determine the impact
of daily 1 g calcium (as CaP) with or without 10 μg vitamin
D3 on bone formation and resorption markers as well as
on calcium, phosphorus, magnesium and iron metabolism
in healthy middle-aged men and women.
Methods
Supplements
Two supplements were used in this study: CaP (Ca5
(PO4)3OH; cfb, Budenheim, Germany) and cholecalciferol
(vitamin D3; Brenntag, Mülheim an der Ruhr, Germany).
In order to achieve a calcium supplementation of additional
1 g/d and a vitamin D3 supplementation of 10 μg/d, CaP
and/or vitamin D3 were incorporated in wholewheat bread.
Participants consumed approximately 135 g of this bread
daily. Placebo bread was prepared in the same manner
as the test bread, but without CaP and vitamin D3. Taste
and visual properties of placebo and test breads were
comparable.
Subjects and study design
The study was conducted at the Friedrich Schiller Univer-
sity Jena, Department of Nutritional Physiology, between
January and April 2011.Sixty omnivorous healthy subjects (men, n = 24; women
n = 36) participated in this double-blind, placebo-controlled
parallel designed study. Eligibility criteria for participants
were age between 20 and 70 years and physical health. All
volunteers were informed of the purpose, the course
and the possible risks of the study and gave their written
consent. The study protocol was approved by the Ethical
Committee of the Friedrich Schiller University Jena (No.:
2959-11/10). Four participants dropped out because of
pregnancy, illness and personal reasons (Figure 1). The
remaining 56 volunteers aged 42 ± 12 y had a BMI of
25 ± 4 kg/m2.
At the beginning of the study (baseline), all subjects
documented their normal nutritional habits in a dietary
record for three successive days. The participants were
encouraged to weigh all eaten foods with proved scales.
One day later, the subjects collected quantitatively their
faeces for three days. From day two to day three of the
faeces collection, the subjects collected their urine for
24 h, too. At the last day of the faeces collection, a fasting
blood sampling took place. This procedure aimed to
familiarise the subjects to the sample collection and to
establish a baseline profile of each subject. Afterwards,
subjects were allocated to the three intervention groups,
so that there were no significant changes in age, BMI and
25-(OH) D concentration between the groups.
After allocation, subjects consumed for two weeks the
placebo bread. Then they consumed for eight weeks either
the CaP, vitamin D3 or the CaP + vitamin D3 bread. In the
last week of the placebo and after four and eight weeks of
intervention, subjects consumed a defined diet for three
days. This diet contained all the foods required per subject
over the three days and was prepared and pre-weighed in
the study centre. The subjects were instructed to consume
no other foods than provided. Food intake was calculated
by weighing food residues. Samples from each food com-
ponent were frozen and stored at −20°C until analysis.
Furthermore, subjects collected faeces quantitatively for
three days, beginning at the second day of the defined diet.
From day two to three of the defined diet, the subjects
collected their urine for 24 h. On the third day of the
defined diet, a fasting venous blood sample was taken.
Sample preparation
Blood samples were drawn by venipuncture and collected
in lithium heparin and serum tubes. Lithium heparin tubes
were centrifuged (2500 × g, 15 min, 20°C) and the plasma
supernatants were stored at −20°C until analysis. Serum
tubes were centrifuged (2500 × g, 10 min, 20°C) and the
serum was stored at −20°C until analysis.
The faecal samples were transported to the study centre
without delay. Each specimen was weighed, frozen and
stored at −20°C. At the end of the study, faeces samples
were homogenised, portioned, and the pH-value was
Figure 1 Flow chart of the study. CaP: tricalcium phosphate; 1,25-(OH)2D: 1alpha,25-dihydroxyvitamin D; 25-(OH)D: 25-hydroxyvitamin D; PTH:
parathormone; CTX: cross-linked C-terminal telopeptide of type I collagen; P1NP: N-terminal propeptide of type I procollagen; DPD: desoxypyridinoline.
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the study centre at the day of the blood sampling. The
urine volume from every participant was measured, and
aliquots were frozen at −20°C until analysis.
Food analysis
The intake of calcium, phosphorus, magnesium, and iron
was analysed via ICP-OES as described previously [10]. The
intake of energy, fat, proteins, carbohydrates and vitamin D
was verified using the Prodi® 5.4 software (Nutri-Science
GmbH, Freiburg, Germany). Retained samples of placebo
and test breads were homogenised, freeze-dried and ana-
lysed for vitamin D3 concentration by certified methods
(GC-MS) according to the Food GmbH Jena, Analytic and
Consulting.
Blood analysis
Concentrations of calcium, phosphate, magnesium, iron,
ferritin and transferrin in plasma and osteocalcin, alkaline
phosphatase, 1alpha,25-dihydroxyvitamin D (1,25-(OH)2D),
25-(OH)D, PTH and calcitonin in serum were ascertained
according to certified methods of the Institute of Clin-
ical Chemistry and Laboratory Medicine, Jena University
Hospital.
Serum cross-linked C-terminal telopeptide of type I colla-
gen (CTX) and N-terminal propeptide of type I procollagen
(P1NP) were determined using methods according to theInstitute of Laboratory Medicine, Clinical Chemistry and
Molecular Diagnostic, University Leipzig.
Faeces and urine analyses
Mineral concentrations in faeces were analysed via ICP-OES
as described previously [10].
The concentrations of calcium, phosphorus, magnesium
and iron in urine were measured according to certified
methods of the Institute of Clinical Chemistry and Labora-
tory Medicine, Jena University Hospital.
The concentrations of CTX and desoxypyridinoline
(DPD) were determined using methods according to the
Institute of Laboratory Medicine, Clinical Chemistry and
Molecular Diagnostic, University Leipzig.
Statistics
Samples from each participant were coded to protect
volunteer identity and to mask treatment groups during
the analysis. All values in the text and tables are means
with standard deviations. Data analysis was performed
using the statistical software package IBM SPSS Statistics
19 (SPSS Inc. IBM Company, Chicago, USA). Variance
homogeneity was tested using the Levene test. In case
of variance heterogeneity data were log10 transformed
(signed with t in text, tables and figures). The effect of
time in each intervention group was tested using general
linear model with repeated measurements (with pairwise
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plementation between groups was tested using univariate
analysis of variance followed by Student-Newman-Keuls
post hoc test. Differences were considered significant at
p ≤ 0.05.
Results
The baseline characteristics of participants of the three
intervention groups are presented in Table 1. Due to
randomisation, there were no significant differences in
age, BMI and 25-(OH)D between intervention groups.
Nutrient intake
There were no differences in the intake of energy, fat, pro-
tein, and carbohydrates between study periods (placebo,
four and eight weeks) and between intervention groups.
The mean intakes of energy, fat, protein, and carbohydrates
were 8.7 ± 1.8 MJ/d, 78.6 ± 22.5 g/d, 73.6 ± 12.5 g/d, and
260.2 ± 47.4 g/d, respectively. Due to the CaP and vitamin
D3 supplementations, the intake of calcium, phosphorus
and vitamin D3 increased significantly (Table 2). The intake
of magnesium and iron did not change between the three
study periods and between the interventions. The mean
magnesium and iron intakes were 277.8 ± 42.2 mg/d and
7.8 ± 1.1 mg/d, respectively.
Minerals
The plasma calcium concentration decreased significantly
in all intervention groups after four and eight weeks of
intervention compared to placebo (Table 3; p ≤ 0.05). In
all interventions, no effect of time on the renal calcium
excretion was observed. After four weeks of intervention,
the CaP group had a significantly higher renal calcium
excretion compared to vitamin D3 (p ≤ 0.05). Due to
CaP supplementations (CaP, CaP + vitamin D3), faecal ex-
cretion of calcium increased significantly after four and
eight weeks compared to placebo. The faecal calcium ex-
cretion was significantly lower in the vitamin D3 group
compared to the CaP and CaP + vitamin D3 groups at four
and eight weeks of intervention (p ≤ 0.05).
There were no changes in plasma phosphate concen-
tration in all intervention groups. After vitamin D3
supplementation, the renal phosphorus excretion signifi-
cantly increased after eight weeks compared to placeboTable 1 Baseline characteristics of participants who
completed the study
CaP Vitamin D3 CaP+vitamin D3
N 19 20 17
Age [y] 42 (12) 45 (13) 41 (12)
BMI [kg/m2] 24 (3) 25 (5) 25 (4)
25-(OH)D [nmol/l] 59 (30) 46 (20) 50 (16)
n = 56; data are expressed as mean (standard deviation); CaP: tricalcium
phosphate; 25-(OH)D: 25-hydroxyvitamin D.(p ≤ 0.05). Due to CaP supplementations (CaP and CaP +
vitamin D3), the faecal excretion of phosphorus increased
significantly after four and eight weeks compared to pla-
cebo. The faecal phosphorus excretion was significantly
lower in the vitamin D3 group compared to the CaP and
the CaP + vitamin D3 groups after eight weeks of interven-
tion (p ≤ 0.05).
Both the plasma magnesium concentration and the faecal
magnesium excretion did not change by any intervention.
After vitamin D3 supplementation, the renal magnesium
excretion significantly increased after eight weeks compared
to four weeks and to placebo (p ≤ 0.05).
Plasma iron, ferritin, transferrin and transferrin saturation
did not change due to any intervention (Table 4). After pla-
cebo and four weeks of intervention, the CaP + vitamin D3
group had significantly higher ferritin concentrations
compared to the CaP group (p ≤ 0.05). The renal iron
concentration was in most cases (67%) below the limit of
detection (0.75 μmol/l) and was not subjected to statistical
analysis.
Bone metabolism markers
Due to the vitamin D3 supplementation, the 25-(OH)D
concentration in plasma significantly increased in the
vitamin D3 group after eight weeks compared to placebo
(Figure 2; p ≤ 0.05). The combined supplementation of
CaP + vitamin D3 led to a significant increase after four and
eight weeks of intervention compared to placebo (p ≤ 0.05).
After CaP intervention, the plasma concentration of 25-
(OH)D significantly decreased after four weeks compared
to placebo (p ≤ 0.05). After four and eight weeks of
intervention, the 25-(OH)D concentration was significantly
higher in the vitamin D3 and CaP + vitamin D3 groups
compared to the CaP group (p ≤ 0.05).
After four and eight weeks of CaP supplementation,
1,25-(OH)2D concentration in plasma decreased signifi-
cantly compared to placebo (Table 5; p ≤ 0.05). After
four weeks of CaP + vitamin D3 intervention, 1,25-(OH)2D
concentration was significantly higher compared to pla-
cebo and eight weeks of CaP + vitamin D3 intervention
(p ≤ 0.05). There were no changes in plasma PTH and
calcitonin concentrations.
Bone resorption markers, serum and urinary CTX and
urinary DPD did not change due to the three interven-
tions (Table 5). The bone formation markers plasma
osteocalcin and serum P1NP did not change after any
intervention. All supplementations led to a significant
increase of plasma alkaline phosphatase concentration
after four weeks compared to placebo and to eight weeks
(Table 5, p ≤ 0.05).
Discussion
The additional intake of 1 g calcium (via CaP) per day was
used in other studies due to beneficial effects on intestinal
Table 2 Mean intake of calcium, phosphorus, and vitamin D during defined diet in all study periods
Parameter Supplements Placebo Interventions
4 weeks 8 weeks
Calcium [mg/d] CaP 938b (197) 1998a (192)1 2014a (194)1
Vitamin D3 905 (187) 897 (219)
2 916 (203)2
CaP+vitamin D3
t 889b (154) 1913a (151)1 1872a (164)1
Phosphorous [mg/d] CaP 1337b (250) 1803a (247)1 1833a (242)1
Vitamin D3 1311 (236) 1303 (247)
2 1324 (226)2
CaP+vitamin D3 1286
b (172) 1733a (180)1 1705a (187)2
Vitamin D3 [μg/d] CaP 6.5 (0.6) 6.6 (0.6)1 6.6 (0.5)1
Vitamin D3 6.2
b (1.3) 15.2a (1.0)2 15.2a (1.0)2
CaP+vitamin D3 6.5
b (0.4) 15.1a (0.4)2 15.1a (0.3)2
n = 56; data are expressed as mean (standard deviation); CaP: tricalcium phosphate; a b mean values within a row with dissimilar superscript letters are
significantly different (p ≤ 0.05); 1 2 mean values within a column with dissimilar superscript numbers are significantly different (p ≤ 0.05); results without
superscripts in a row/column have no significant differences; effect of time was tested using general linear model with repeated measurements (with pairwise
comparisons based on Fishers-LSD test); effect of supplementation was tested using univariate analysis of variance followed by Student-Newman-Keuls post hoc
test.; t for statistical analysis the data were log10 transformed, because of variance heterogeneity.
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vitamin D3 was chosen, because 5 μg/d was the previously
recommended vitamin D intake in Germany [14]. In 2012,
the German Nutrition Society set up this value to 20 μg/d
for adolescents and adults under 65 years [15], because
the UV index in Germany is lower than 3 for about six
months of the year [16]. A rule of thumb says, that in-
dexes lower than 3 are insufficient to produce vitamin D
in the skin [16]. In the present study, the total intake of
vitamin D (supplement, defined diet and bread) was ap-
proximately 15 μg/d in the vitamin D3-supplemented
groups, and therefore below the actual recommendation
of the German Nutrition Society [15].
However, after vitamin D3 supplementation, the 25-(OH)D
concentration significantly increased after eight weeks
(Figure 2). The mean increases in the vitamin D3 and in the
CaP + vitamin D3 groups were 22.5 nmol/l and 19.8 nmol/l,
respectively (Figure 2). The present results indicate, that
the supplementation with 10 μg/d was enough to increase
25-(OH)D significantly. Only 5% of participants treated
with vitamin D3 had 25-(OH)D concentrations below
50 nmol/l after eight weeks of intervention. Furthermore,
the mean increase is in accordance with other vitamin D3
supplementation studies [17,18].
Interestingly, in the CaP + vitamin D3 group the increase
in 25-(OH)D was significant after four and eight weeks, but
in the vitamin D3 group only after eight weeks (Figure 2).
It seems that the combination with CaP leads to a faster
increase in 25-(OH)D concentration. A low calcium intake
could lead to a higher turnover of vitamin D metabolites
(higher production of 1,25-(OH)2D, due to PTH increase),
while a high calcium intake could be 25-(OH)D sparing
[19]. These findings were based on rat experiments, in
which the half-life of 25-(OH)D was longer when cal-
cium intake was high. Furthermore, in a rat experimentconducted by Anderson et al., animals fed high calcium
combined with vitamin D3 had significantly higher serum
25-(OH)D concentrations compared to animals fed low
calcium combined with vitamin D3 [20]. In the present
study, plasma calcium and PTH were not significantly
affected by the interventions. Only the 1,25-(OH)2D
concentration decreased compared to placebo after eight
weeks of CaP (CaP alone and CaP + vitamin D3) supple-
mentations. From the increase of 25-(OH)D concentration
after four weeks of CaP + vitamin D3 supplementation it
can be concluded, that the combination of vitamin D3 and
calcium is more effective than vitamin D3 alone.
In the present study, we determined different biomarkers
of bone metabolism, like urinary CTX, serum CTX and
urinary DPD for bone resorption and plasma alkaline
phosphatase, serum P1NP and plasma osteocalcin for
bone formation. None of the bone metabolism markers
changed related to the CaP, vitamin D3 or CaP + vitamin
D3 supplementations. Literature indicates that a modula-
tion of bone metabolism through calcium and/or vitamin
D supplementations occurred especially in older subjects
with a vitamin D deficiency [12,21]. In studies involv-
ing subjects with no or only marginal vitamin D defi-
ciency, no beneficial effects on bone metabolism were
observed [22,23].
Due to CaP supplementation, the faecal excretion of
calcium and phosphorus significantly increased. This is
based on the formation of amorphous calcium phosphate,
a well-known process in the intestine [8,24]. Thus, only a
minor part of the calcium can be absorbed [11]. The un-
changed excretion of calcium and phosphorus in urine
and the comparable plasma concentration confirm this
suggestion. Vitamin D is known to increase the absorption
of calcium and phosphate in the human gut, in order to
maintain the calcium homeostasis. After supplementation
Table 3 Concentrations of plasma and excretion of renal and faecal minerals after intervention with either tricalcium
phosphate, vitamin D3 or both
Parameter Supplements Placebo Interventions
4 weeks 8 weeks
Plasma calcium [mmol/l] CaP 2.4a (0.1) 2.3b (0.1) 2.3b (0.1)
Vitamin D3 2.4
a (0.1) 2.3b (0.1) 2.3b (0.1)
CaP+vitamin D3 2.4
a (0.1) 2.3b (0.1) 2.4b (0.1)
Renal calcium excretion [mg/d] CaP 158 (84) 187 (98)1 171 (79)
Vitamin D3 133 (53) 141 (64)
2 152 (58)
CaP+vitamin D3 117 (60) 143 (63)
12 130 (57)
Faecal calcium excretion [mg/d] CaP 763a (434) 1214b (386)1 1324b (465)1
Vitamin D3 810 (328) 723 (366)
2 708 (423)2
CaP+vitamin D3 657
a (318) 1149b (426)1 1254b (449)1
Plasma phosphate concentration [mmol/l] CaP 1.1 (0.1) 1.2 (0.2) 1.1 (0.1)
Vitamin D3 1.1 (0.1) 1.1 (0.2) 1.1 (0.1)
CaP+vitamin D3 1.2 (0.1) 1.2 (0.1) 1.1 (0.2)
Renal phosphorus excretion [mg/d] CaP 917 (354) 881 (289) 816 (289)
Vitamin D3 857
a (236) 841ab (276) 963b (300)
CaP+vitamin D3 807 (276) 818 (290) 894 (288)
Faecal phosporus excretion [mg/d] CaP 554a (382) 716b (331) 754b (331)1
Vitamin D3 584 (218) 544 (309) 450 (275)
2
CaP+vitamin D3 496
a (229) 696b (270) 740b (260)1
Plasma magnesium concentration [mmol/l] CaP 0.9 (0.1) 0.9 (0.1) 0.9 (0.1)
Vitamin D3 1.0 (0.1) 0.9 (0.0) 0.9 (0.0)
CaP+vitamin D3 0.9 (0.1) 0.9 (0.1) 0.9 (0.0)
Renal magnesium excretion [mg/d] CaP 93 (41) 90 (45) 86 (31)
Vitamin D3 79
a (23) 84a (30) 98b (31)
CaP+vitamin D3 75 (31) 76 (25) 73 (26)
Faecal magnesium excretion [mg/d] CaP 207 (136) 191 (103) 208 (119)
Vitamin D3 234 (85) 242 (135) 205 (97)
CaP+vitamin D3 191 (74) 178 (56) 180 (54)
n = 56; data are expressed as mean (standard deviation); CaP: tricalcium phosphate; a b mean values within a row with dissimilar superscript letters are
significantly different (p ≤ 0.05); 1 2 mean values within a column with dissimilar superscript numbers are significantly different (p ≤ 0.05); results without
superscripts in a row/column have no significant differences; effect of time was tested using general linear model with repeated measurements (with pairwise
comparisons based on Fishers-LSD test); effect of supplementation was tested using univariate analysis of variance followed by Student-Newman-Keuls post
hoc test.
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significantly increased after eight weeks compared to
placebo. In phosphorus equilibrium, the amounts of
intestinally absorbed phosphorus is equal to the excreted
phosphorus by the kidney [25]. Thus, the increased excre-
tion indicates higher phosphorus absorption due to vitamin
D3 supplementation.
In a rat experiment, it has been shown that magnesium
is also able to form an insoluble complex with calcium
and phosphate [26]. When this formation occurs in the
human gut, the absorption of magnesium would be
inhibited. After supplementation with high amounts of
phosphorus, Greger et al. showed a significant increasein faecal excretion of magnesium, but simultaneously a
decrease of magnesium in urinary excretion [27]. The
authors concluded that magnesium metabolism was not
negatively influenced by high phosphorus doses [27]. In
the present study, CaP supplementation had no harmful
effects on magnesium metabolism. After eight weeks of
vitamin D3 supplementation, the renal excretion of mag-
nesium increased compared to placebo. Hardwick et al.
reviewed the literature concerning magnesium absorption
and suggested that a significant amount of magnesium
absorption is vitamin D-dependent [28].
Literature indicates, that calcium supplementation can
decrease iron absorption, both from haem and non-haem
Table 4 Parameter of iron status after intervention with either tricalcium phosphate, vitamin D3 or both
Parameter Supplements Placebo Interventions
4 weeks 8 weeks
Plasma iron concentration [μmol/l] CaP 18.8 (5.4) 18.3 (7.3) 19.5 (6.5)
Vitamin D3 22.3 (5.2) 20.8 (6.8) 20.5 (5.1)
CaP+vitamin D3 18.8 (6.7) 21.5 (5.2) 20.5 (5.5)
Plasma transferrin concentration [g/l] CaP 2.5 (0.4) 2.4 (0.5) 2.5 (0.4)
Vitamin D3 2.7 (0.5) 2.6 (0.5) 2.6 (0.6)
CaP+vitamin D3 2.7 (0.4) 2.7 (0.4) 2.8 (0.6)
Transferrin saturation [%] CaP 31.1 (10.1) 32.3 (16,8) 32.9 (10.9)
Vitamin D3 35.0 (11.2) 24.1 (14.4) 33.6 (9.2)
CaP+vitamin D3 29.1 (13.2) 32.0 (8.7) 31.3 (12.3)
Plasma ferritin [μg/l] CaP 54.1 (28.4)1 47.5 (21.7)1 45.4 (22.6)
Vitamin D3 88.3 (65.1)
12 81.0 (60.1)12 72.6 (43.4)
CaP+vitamin D3 134.6 (138.5)
2 139.3 (151.3)2 105.0 (99.6)
Faecal iron excretion [mg/d] CaP 8.7 (6.4) 7.7 (4.5) 7.7 (4.0)
Vitamin D3 9.1 (4.0) 9.5 (5.0) 8.3 (3.7)
CaP+vitamin D3 7.4 (2.9) 6.7 (2.4) 7.3 (2.9)
n = 51, except plasma transferrin n = 50; data are expressed as mean (standard deviation); CaP: tricalcium phosphate; 1 2 mean values within a column with
dissimilar superscript numbers are significantly different (p ≤ 0.05); results without superscripts in a row/column have no significant differences; effect of time was
tested using general linear model with repeated measurements (with pairwise comparisons based on Fishers-LSD test); effect of supplementation was tested using
univariate analysis of variance followed by Student-Newman-Keuls post hoc test.
Figure 2 Concentration of plasma 25-(OH)D after intervention with either tricalcium phosphate, vitamin D3 or both. n =55; CaP:
tricalcium phosphate; 25-(OH)D: 25-hydroxyvitamin D; broken line: recommended 25-(OH)D concentration; dotted line: optimal 25-(OH)D
concentration; a b data are expressed as mean and standard deviation; mean values within a row with dissimilar superscript letters are
significantly different (p ≤ 0.05); * significant difference between groups; effect of time was tested using general linear model with repeated
measurements (with pairwise comparisons based on Fishers-LSD test); effect of supplementation was tested using univariate analysis of
variance followed by Student-Newman-Keuls post hoc test.
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Table 5 Bone metabolism markers and bone-related hormones in blood and urine after intervention with either
tricalcium phosphate, vitamin D3 or both
Parameter Supplements Placebo Interventions
4 weeks 8 weeks
Plasma 1,25-(OH)2D [pmol/l] CaP
t 102.9a (24.7) 93.3b (24.7) 76.3c (24.5)
Vitamin D3
t 97.9 (27.5) 108.3 (23.9) 99.2 (38.1)
CaP+vitamin D3
t 92.2b (31.0) 100.4a (31.1) 86.0b (23.1)
Plasma osteocalcin [ng/ml] CaP 20.3 (6.5) 20.4 (6.5) 20.9 (7.2)
Vitamin D3 21.8 (7.2) 23.4 (8.2) 20.7 (8.8)
CaP+vitamin D3 20.1 (7.0) 20.2 (6.4) 19.9 (7.6)
Plasma alkaline phosphatase CaP 9.6a (3.9) 10.7b (3.9) 9.3a (3.7)
Vitamin D3 9.1
a (3.5) 10.3b (3.6) 9.0a (3.6)
CaP+vitamin D3 9.8
a (3.4) 11.3b (3.9) 9.5a (3.1)
Serum PTH [μg/l] CaP 56.6 (12.2) 74.4 (35.8) 71.9 (25.1)
Vitamin D3 65.0 (24.7) 71.2 (29.2) 66.5 (21.0)
CaP+vitamin D3 62.0 (20.1) 63.3 (17.8) 60.6 (19.8)
Serum CTX [ng/ml] CaP 0.3 (0.1) 0.2 (0.1) 0.3 (0.2)
Vitamin D3 0.3 (0.2) 0.3 (0.2) 0.3 (0.1)
CaP+vitamin D3 0.3 (0.1) 0.2 (0.1) 0.2 (0.1)
Serum P1NP [ng/ml] CaP 44.5 (19.1) 42.5 (16.5) 44.2 (19.7)
Vitamin D3 48.8 (18.9) 44.4 (20.7) 50.9 (24.7)
CaP+vitamin D3 41.4 (17.6) 36.3 (19.7) 40.4 (15.9)
Urine DPD [nmol/l] CaP 29.2 (14.9) 31.6 (20.0) 27.0 (14.5)
Vitamin D3 25.3 (13.7) 22.8 (11.5) 25.5 (9.8)
CaP+vitamin D3 23.7 (9.0) 25.8 (16.0) 28.1 (15.2)
Urine CTX [mg/l] CaP 1.0 (0.6) 1.1 (1.1) 0.7 (0.5)
Vitamin D3 0.9 (0.7) 0.8 (0.6) 1.1 (0.6)
CaP+vitamin D3 0.9 (0.7) 0.9 (0.7) 1.2 (1.1)
n = 55; data are expressed as mean (standard deviation); CaP: tricalcium phosphate; 1,25-(OH)2D: 1alpha,25-dihydroxyvitamin D; 25-(OH)D: 25-hydroxyvitamin D;
PTH: parathormone; CTX: cross-linked C-terminal telopeptide of type I collagen; P1NP: N-terminal propeptide of type I procollagen; DPD: desoxypyridinoline;
a b mean values within a row with dissimilar superscript letters are significantly different (p ≤ 0.05); results without superscripts in a row/column have no significant
differences; effect of time was tested using general linear model with repeated measurements (with pairwise comparisons based on Fishers-LSD test); effect of
supplementation was tested using univariate analysis of variance followed by Student-Newman-Keuls post hoc test; t for statistical analysis the data were log10
transformed, because of variance heterogeneity.
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http://www.nutritionj.com/content/13/1/6iron [29]. This decrease in iron absorption has been shown
mostly in short-term studies [30-32]. In contrast, Minihane
and Fairweather-Tait supplemented calcium carbonate in a
short-term (1200 mg calcium carbonate for one day) and in
a long-term study (1200 mg calcium carbonate over six
months) and showed that the non-haem iron absorption
decreased only in the short-term supplementation [33].
By supplementing 1200 mg calcium as calcium carbonate
over six months, they found no changes in any of the
haematologic indexes (i.e. haemoglobin, plasma ferritin).
The mechanism proposed by the authors is an adaptive
response in the intestinal mucosa cell: the lower supply of
iron to plasma after calcium intake may modify the devel-
oping enterocytes in order to stimulate specific proteins
[33]. Thus, the dietary iron is used more efficiently, when
developing cells are mature [33]. The unchanged resultsof faecal iron and of iron status on the present study
indexes (transferrin, transferrin saturation, ferritin) confirm
the results of Minihane and Fairweather-Tait, that long-
term CaP supplementation does not negatively influence
the parameters of iron metabolism. The significantly higher
ferritin concentration in the CaP + vitamin D3 is due to two
participants with concentrations in the upper limits of
normal. In all, the presented results underline that supple-
mentation with CaP and/or vitamin D3 did not negatively
influence the metabolism of magnesium and iron.
Conclusion
The results of the present human study shows that sup-
plementation with 10 μg vitamin D3 significantly increases
25-(OH)D. Furthermore, a combination with 1 g calcium
(as CaP) beneficially influences the increasing effect on
Trautvetter et al. Nutrition Journal 2014, 13:6 Page 9 of 9
http://www.nutritionj.com/content/13/1/6the 25-(OH)D concentration. Both CaP alone or in
combination with vitamin D3 has no beneficial or harmful
effects on bone metabolism markers and on the metabolism
of calcium, phosphorus, magnesium and iron in middle-
aged healthy persons.
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